Company intelligence / Profile preview

Potomac Pharma, Inc.

Not specified*, Maryland, United Statespotomaccarepharmacy.com ↗

Ownership: Private
Development stage: Commercial

Overview

Potomac Pharma, Inc. was a Maryland-based private biotech/pharmaceutical company focused on developing small molecule therapeutics targeting the alpha-2 adrenergic receptor for central nervous system disorders such as schizophrenia and cognition disorders. Its two main programs—P‑101 and Idazoxan Hydrochloride—were both discontinued before reaching late-stage clinical trials.[1][7] There are no recent reports of ongoing clinical results or new pipeline assets.

Therapeutic areas: PsychiatryNeurology
Modalities: Small molecules (e.g., ADRA2 antagonists such as Idazoxan Hydrochloride and P-101)
Industry: Biotech

Beyond the preview

Go deeper on Potomac Pharma, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Potomac Pharma, Inc..

Explore the full profile